# A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients

> **NCT05815901** · PHASE3 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 612 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Epaminurad 6 mg
- **DRUG:** Epaminurad 9 mg
- **DRUG:** Febuxostat 40 mg
- **DRUG:** Febuxostat 80 mg
- **DRUG:** Epaminurad 6 mg placebo
- **DRUG:** Epaminurad 9 mg placebo
- **DRUG:** Febuxostat 40 mg placebo
- **DRUG:** Febuxostat 80 mg placebo

## Key facts

- **NCT ID:** NCT05815901
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2024-03-26
- **Final completion:** 2026-04-23
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815901, "A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05815901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*